Printer Friendly

Global Pharmaceutical Contract Manufacturing Industry.

NEW YORK, Aug. 12, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Pharmaceutical Contract Manufacturing Industry

http://www.reportlinker.com/p02284882/Global-Pharmaceutical-Contract-Manufacturing-Industry.html

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms: Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 92 companies including many key and niche players such as -

AAIPharma Services Corporation

Aenova Group

Ajinomoto Althea, Inc.

Albany Molecular Research, Inc.

Dishman

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

A Curtain Raiser II-1

Cost and Risk Containment Objectives Spur Outsourcing of

Biopharma Production II-2

Key Market Drivers II-2

Biopharma Contract Manufacturing Market Emerges from the

Recessionary Lull II-3

Table 1: Worldwide Funding for Biotech Projects by Geographic

Region (2012): Percentage Breakdown of Funding for North

America, Europe, and Rest of World (includes corresponding

Graph/Chart) II-3

Table 2: Worldwide Funding for Biotech Projects by Product

Development Phase (2012): Percentage Breakdown of Funding for

Products in Clinical Trial, Pre-Clinical Trial and

Commercialization Phases (includes corresponding Graph/Chart) II-4

Favorable Trends in the Pharma Industry Portend Bright Outlook

for the PCM Market II-4

Ballooning Global Population Offers Increased Growth

Opportunities II-4

Table 3: Top 25 Countries Worldwide in Terms of Population:

2007, 2010 & 2013 II-5

Surge in Generic Drugs to Benefit Pharmaceutical Contract

Manufacturers II-5

Table 4: Worldwide Annual Spending on Drugs by Category

(2011 & 2015): Percentage Breakdown of Dollar Sales for

Branded Drugs, Generic Drugs, and Others (includes

corresponding Graph/Chart) II-6

Increasing Consumption Drugs within Aging Population Boosts

Opportunities for PCM II-6

Table 5: Global Population Statistics for the 65+ Age Group

(2012) (includes corresponding Graph/Chart) II-7

Table 6: Elderly Population (65+ Years) as a % of Total

Population (2025) (includes corresponding Graph/Chart) II-8

Changing Healthcare Expenditure Trends to Spur Demand for

Contract Manufacturing of Generics II-8

Table 7: Healthcare Spending as a Percentage of GDP: 2012

(includes corresponding Graph/Chart) II-10

US and Europe Dominate Market, Asia-Pacific Lends Growth Momentum II-10

Major Changes Imperative to Capitalize on Brighter Future

Prospects II-11

Solid Dosage Form Retains Popularity among Pharma Contract

Manufacturers II-11

Injectable-Dose Formulations to Spearhead Growth of the PCM

Market II-12

2. MAJOR MARKET TRENDS & ISSUES II-14

Patent Expiries Augur Good Tidings for the PCM Market II-14

PCMs Gear Up to Tap Booming Biologics Market II-14

PCM Market for Vaccines Yet to Take Off II-14

Biotechnology Upstarts Spur Demand for Contract Manufacturing II-15

Vendor Switching- A Growing Concern for PCMs II-15

Marked Decrease Witnessed in Venture Capital Investment into

PCM Upstarts II-16

PCM Industry Gravitates Eastward, and Subsequently Leads to

Near-Shoring II-16

Adoption of Cutting-Edge Technologies to Radicalize PCM

Environment II-17

RABS technology II-17

Quality by Design II-18

Track & Trace Techniques II-18

Disposable Processing Techniques II-18

Upstream & Downstream Processes II-18

Process Analytical Technology II-19

Near Infrared Spectroscopy II-19

Increased Regulator Scrutiny: A Cause of Concern for the

Emerging Market PCMs II-19

3. COMPETITIVE LANDSCAPE II-20

PCM - A Highly Fragmented Industry Undergoing Consolidation II-20

Table 8: Worldwide Pharmaceutical Contract Manufacturing

Market by Leading Players (2013): Percentage Breakdown of

Value Sales for Catalent Pharma Solutions, DPx Holdings B.V.,

Famar Health Care Services, and Others (includes

corresponding Graph/Chart) II-20

Table 9: Worldwide Injectables Contract Manufacturing Market

by Leading Players (2013): Percentage Breakdown of Value

Sales for Baxter, Hospira, Vetter and Others (includes

corresponding Graph/Chart) II-20

PCMs Battle Fierce Competition and Commoditization II-20

Large Enterprises Edging Out Small-scale Players II-21

Competitive Pricing Pressure to Spur Consolidation II-21

Competition Heats Up in Injectables Market, PCMs Expand

Capabilities and Service Offerings II-22

4. SERVICE OVERVIEW II-23

Introduction II-23

Injectables (Injections, Vials, and IV solutions) II-23

Solid Dosage Forms (SDFs) (Tablets and Capsules) II-23

Liquid Dosage Forms (LDFs) (Syrups and Suspensions) II-24

An Insight into the Rise of Pharmaceutical Contract Manufacturing II-24

Investment Risks in Pharmaceutical Contract Manufacturing II-25

Quality Assurance Risk II-25

Drug Development Risk II-25

Acquisition Risk II-25

Client Dependency Risk II-25

5. RECENT INDUSTRY ACTIVITY II-26

Onyx Announces completion of API project with Neuronascent II-26

Meiji Holdings Buys Medreich Lifecare Limited II-26

Emilia Group Takes Over Pharma Pac LLC II-26

AMRI to Take Over Cedarburg Pharma II-26

AMRI to Acquire OsoBio Biopharmaceuticals Manufacturing II-26

Royal DSM's DPP Merges with JLL Partners' Pantheon, Giving

Rise to DPx Holdings B.V. II-26

Emergent BioSolutions Takes Over Cangene Corporation II-26

Dendreon Appoints PharmaCell as European CMO II-27

Ajinomoto Acquires Althea Technologies II-27

Aenova Group Merges with Haupt Pharma II-27

Kemwell Biopharma Takes Over Cirrus Pharmaceuticals II-27

Questcor Acquires BioVectra II-27

ICON Buys Cross Country Healthcare's Clinical Trial Services

Division II-27

Columbia Laboratories Acquires Molecular Profiles II-27

EPS Corp Acquires Gleneagles CRC from IHH Healthcare II-27

Capsugel to Take Over Bend Research II-28

Gallus BioPharmaceutical Takes Over Laureate Biopharmaceutical II-28

PLI Holdings Acquires Pfanstiehl Laboratories II-28

DPT Laboratories Announce Integration With Confab II-28

Nordion Inks Contract Manufacturing Agreement with Navidea II-28

Unilife Receives Injectables Contract from Hikma II-28

NextPharma Technologies Expands Bielefeld Production Capacity

and Capabilities II-28

Fuji Pharma to Acquire OLIC from DKSH II-28

DSM Pharmaceutical Partners Almac Group II-28

Metrics Inc Introduces Generic Drug of Oxycodone HCl 5mg II-29

Patheon Completes Acquires Banner Pharmacaps II-29

PAREXEL International Acquires Liquent II-29

American Capital Acquires Cambridge Major II-29

Aenova Group Takes Over Euro Vital Pharma II-29

Althea Technologies Receives Contract from Pfenex II-29

6. FOCUS ON SELECT GLOBAL PLAYERS II-30

AAIPharma Services Corporation (US) II-30

Aenova Group (Germany) II-30

Haupt Pharma AG (Germany) II-30

Ajinomoto Althea, Inc. (US) II-31

Albany Molecular Research Inc. (US) II-31

Boehringer Ingelheim GmbH (Germany) II-32

Catalent Pharma Solutions, Inc. (US) II-32

Dishman (India) II-33

DPx Holdings B.V. (US) II-33

Famar Health Care Services (Greece) II-34

Hospira, Inc. (US) II-34

Jubilant Life Sciences Limited (India) II-34

Kemwell Biopharma Pvt. Ltd (India) II-35

Lonza Group Ltd. (Switzerland) II-35

NextPharma Technologies Holding Ltd (UK) II-36

Nipro Pharma Corporation (Japan) II-36

Recipharm AB (Sweden) II-37

Cobra Biologics Holding AB (Sweden) II-37

7. GLOBAL MARKET PERSPECTIVE II-38

Table 10: World Recent Past, Current and Future Analysis for

Pharmaceutical Contract Manufacturing by Geographic Region -

US, Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets Independently Analyzed with Annual Revenue Figures in

US$ Thousand for the Years 2013 through 2020 (includes

corresponding Graph/Chart) II-38

Table 11: World Historic Review for Pharmaceutical Contract

Manufacturing by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific and Rest of World Markets Independently

Analyzed with Annual Revenue Figures in US$ Thousand for the

Years 2006 through 2012 (includes corresponding Graph/Chart) II-39

Table 12: World 15-Year Perspective for Pharmaceutical

Contract Manufacturing by Geographic Region - Percentage

Breakdown of Annual Revenues for US, Canada, Japan, Europe,

Asia-Pacific and Rest of World Markets for the Years 2006,

2014 and 2020 (includes corresponding Graph/Chart) II-40

Table 13: World Recent Past, Current and Future Analysis for

Pharmaceutical Contract Manufacturing of Injectables

(Injections, Vials & Intravenous Solutions) by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of

World Markets Independently Analyzed with Annual Revenue

Figures in US$ Thousand for the Years 2013 through 2020

(includes corresponding Graph/Chart) II-41

Table 14: World Historic Review for Pharmaceutical Contract

Manufacturing of Injectables (Injections, Vials & Intravenous

Solutions) by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific and Rest of World Markets Independently Analyzed

with Annual Revenue Figures in US$ Thousand for the Years 2006

through 2012 (includes corresponding Graph/Chart) II-42

Table 15: World 15-Year Perspective for Pharmaceutical

Contract Manufacturing of Injectables (Injections, Vials &

Intravenous Solutions) by Geographic Region - Percentage

Breakdown of Annual Revenues for US, Canada, Japan, Europe,

Asia-Pacific and Rest of World Markets for the Years 2006,

2014 and 2020 (includes corresponding Graph/Chart) II-43

Table 16: World Recent Past, Current and Future Analysis for

Pharmaceutical Contract Manufacturing of Solid Dosage Forms

(Tablets & Capsules) by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific and Rest of World Markets Independently

Analyzed with Annual Revenue Figures in US$ Thousand for the

Years 2013 through 2020 (includes corresponding Graph/Chart) II-44

Table 17: World Historic Review for Pharmaceutical Contract

Manufacturing of Solid Dosage Forms (Tablets & Capsules) by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

and Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Thousand for the Years 2006 through

2012 (includes corresponding Graph/Chart) II-45

Table 18: World 15-Year Perspective for Pharmaceutical

Contract Manufacturing of Solid Dosage Forms (Tablets &

Capsules) by Geographic Region - Percentage Breakdown of

Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific

and Rest of World Markets for the Years 2006, 2014 and 2020

(includes corresponding Graph/Chart) II-46

Table 19: World Recent Past, Current and Future Analysis for

Pharmaceutical Contract Manufacturing of Liquid & Semi-solid

Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments)

by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

and Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Thousand for the Years 2013 through

2020 (includes corresponding Graph/Chart) II-47

Table 20: World Historic Review for Pharmaceutical Contract

Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups,

Suspensions, Gels, Creams & Ointments) by Geographic Region -

US, Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets Independently Analyzed with Annual Revenue Figures in

US$ Thousand for the Years 2006 through 2012 (includes

corresponding Graph/Chart) II-48

Table 21: World 15-Year Perspective for Pharmaceutical

Contract Manufacturing of Liquid & Semi-solid Dosage Forms

(Syrups, Suspensions, Gels, Creams & Ointments) by Geographic

Region - Percentage Breakdown of Annual Revenues for US,

Canada, Japan, Europe, Asia-Pacific and Rest of World Markets

for the Years 2006, 2014 and 2020 (includes corresponding

Graph/Chart) II-49

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

US PCM Market Overview III-1

Competitive Landscape III-2

Strategic Corporate Developments III-2

Select Key Players III-4

B.Market Analytics III-7

Table 22: The US Recent Past, Current and Future Analysis

for Pharmaceutical Contract Manufacturing by Dosage Form -

Injectables (Injections, Vials & Intravenous Solutions),

Solid Dosage Forms (Tablets & Capsules) and Liquid &

Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams &

Ointments) Independently Analyzed with Annual Revenue

Figures in US$ Thousand for the Years 2013 through 2020

(includes corresponding Graph/Chart) III-7

Table 23: The US Historic Review for Pharmaceutical Contract

Manufacturing by Dosage Form - Injectables (Injections,

Vials & Intravenous Solutions), Solid Dosage Forms (Tablets &

Capsules) and Liquid & Semi-solid Dosage Forms (Syrups,

Suspensions, Gels, Creams & Ointments) Independently

Analyzed with Annual Revenue Figures in US$ Thousand for the

Years 2006 through 2012 (includes corresponding Graph/Chart) III-8

Table 24: The US 15-Year Perspective for Pharmaceutical

Contract Manufacturing by Dosage Form - Percentage Breakdown

of Annual Revenues for Injectables (Injections, Vials &

Intravenous Solutions), Solid Dosage Forms (Tablets &

Capsules) and Liquid & Semi-solid Dosage Forms (Syrups,

Suspensions, Gels, Creams & Ointments) for the Years 2006,

2014 and 2020 (includes corresponding Graph/Chart) III-9

2. CANADA III-10

A.Market Analysis III-10

Strategic Corporate Developments III-10

B.Market Analytics III-11

Table 25: Canadian Recent Past, Current and Future Analysis

for Pharmaceutical Contract Manufacturing by Dosage Form -

Injectables (Injections, Vials & Intravenous Solutions),

Solid Dosage Forms (Tablets & Capsules) and Liquid &

Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams &

Ointments) Independently Analyzed with Annual Revenue

Figures in US$ Thousand for the Years 2013 through 2020

(includes corresponding Graph/Chart) III-11

Table 26: Canadian Historic Review for Pharmaceutical

Contract Manufacturing by Dosage Form - Injectables

(Injections, Vials & Intravenous Solutions), Solid Dosage

Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage

Forms (Syrups, Suspensions, Gels, Creams & Ointments)

Independently Analyzed with Annual Revenue Figures in US$

Thousand for the Years 2006 through 2012 (includes

corresponding Graph/Chart) III-12

Table 27: Canadian 15-Year Perspective for Pharmaceutical

Contract Manufacturing by Dosage Form - Percentage Breakdown

of Annual Revenues for Injectables (Injections, Vials &

Intravenous Solutions), Solid Dosage Forms (Tablets &

Capsules) and Liquid & Semi-solid Dosage Forms (Syrups,

Suspensions, Gels, Creams & Ointments) for the Years 2006,

2014 and 2020 (includes corresponding Graph/Chart) III-13

3. JAPAN III-14

A.Market Analysis III-14

Strategic Corporate Development III-14

Nipro Pharma Corporation - A Key Japanese Player III-14

B.Market Analytics III-15

Table 28: Japanese Recent Past, Current and Future Analysis

for Pharmaceutical Contract Manufacturing by Dosage Form -

Injectables (Injections, Vials & Intravenous Solutions),

Solid Dosage Forms (Tablets & Capsules) and Liquid &

Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams &

Ointments) Independently Analyzed with Annual Revenue

Figures in US$ Thousand for the Years 2013 through 2020

(includes corresponding Graph/Chart) III-15

Table 29: Japanese Historic Review for Pharmaceutical

Contract Manufacturing by Dosage Form - Injectables

(Injections, Vials & Intravenous Solutions), Solid Dosage

Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage

Forms (Syrups, Suspensions, Gels, Creams & Ointments)

Independently Analyzed with Annual Revenue Figures in US$

Thousand for the Years 2006 through 2012 (includes

corresponding Graph/Chart) III-16

Table 30: Japanese 15-Year Perspective for Pharmaceutical

Contract Manufacturing by Dosage Form - Percentage Breakdown

of Annual Revenues for Injectables (Injections, Vials &

Intravenous Solutions), Solid Dosage Forms (Tablets &

Capsules) and Liquid & Semi-solid Dosage Forms (Syrups,

Suspensions, Gels, Creams & Ointments) for the Years 2006,

2014 and 2020 (includes corresponding Graph/Chart) III-17

4. EUROPE III-18

A.Market Analysis III-18

European PCM Market Caught in Eurodebt Doldrums III-18

Injectables Segment Offers Promising Potential III-18

Mammalian Cell Technology Dominates PCM Market III-19

Competitive Scenario III-19

Overview of Select Markets III-19

Germany III-19

Russia III-19

Strategic Corporate Developments III-20

Select Key Players III-21

B.Market Analytics III-24

Table 31: European Recent Past, Current and Future Analysis

for Pharmaceutical Contract Manufacturing by Dosage Form -

Injectables (Injections, Vials & Intravenous Solutions),

Solid Dosage Forms (Tablets & Capsules) and Liquid &

Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams &

Ointments) Independently Analyzed with Annual Revenue

Figures in US$ Thousand for the Years 2013 through 2020

(includes corresponding Graph/Chart) III-24

Table 32: European Historic Review for Pharmaceutical

Contract Manufacturing by Dosage Form - Injectables

(Injections, Vials & Intravenous Solutions), Solid Dosage

Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage

Forms (Syrups, Suspensions, Gels, Creams & Ointments)

Independently Analyzed with Annual Revenue Figures in US$

Thousand for the Years 2006 through 2012 (includes

corresponding Graph/Chart) III-25

Table 33: European 15-Year Perspective for Pharmaceutical

Contract Manufacturing by Dosage Form - Percentage Breakdown

of Annual Revenues for Injectables (Injections, Vials &

Intravenous Solutions), Solid Dosage Forms (Tablets &

Capsules) and Liquid & Semi-solid Dosage Forms (Syrups,

Suspensions, Gels, Creams & Ointments) for the Years 2006,

2014 and 2020 (includes corresponding Graph/Chart) III-26

5. ASIA-PACIFIC III-27

A.Market Analysis III-27

Favorable Government Policies Transform China and India into

PCM Hubs III-27

Competitive Scenario III-27

Overview of Select Regional Markets III-28

China III-28

Outsourcing Industry Bogged Down by Recession III-28

India III-28

Indian PCMs Battle Soaring Costs III-29

Strategic Corporate Developments III-29

Select Key Players III-29

B.Market Analytics III-31

Table 34: Asia-Pacific Recent Past, Current and Future

Analysis for Pharmaceutical Contract Manufacturing by Dosage

Form - Injectables (Injections, Vials & Intravenous

Solutions), Solid Dosage Forms (Tablets & Capsules) and

Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels,

Creams & Ointments) Independently Analyzed with Annual

Revenue Figures in US$ Thousand for the Years 2013 through

2020 (includes corresponding Graph/Chart) III-31

Table 35: Asia-Pacific Historic Review for Pharmaceutical

Contract Manufacturing by Dosage Form - Injectables

(Injections, Vials & Intravenous Solutions), Solid Dosage

Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage

Forms (Syrups, Suspensions, Gels, Creams & Ointments)

Independently Analyzed with Annual Revenue Figures in US$

Thousand for the Years 2006 through 2012 (includes

corresponding Graph/Chart) III-32

Table 36: Asia-Pacific 15-Year Perspective for

Pharmaceutical Contract Manufacturing by Dosage Form -

Percentage Breakdown of Annual Revenues for Injectables

(Injections, Vials & Intravenous Solutions), Solid Dosage

Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage

Forms (Syrups, Suspensions, Gels, Creams & Ointments) for

the Years 2006, 2014 and 2020 (includes corresponding

Graph/Chart) III-33

6. REST OF WORLD III-34

Market Analysis III-34

Table 37: Rest of World Recent Past, Current and Future

Analysis for Pharmaceutical Contract Manufacturing by Dosage

Form - Injectables (Injections, Vials & Intravenous

Solutions), Solid Dosage Forms (Tablets & Capsules) and

Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels,

Creams & Ointments) Independently Analyzed with Annual

Revenue Figures in US$ Thousand for the Years 2013 through

2020 (includes corresponding Graph/Chart) III-34

Table 38: Rest of World Historic Review for Pharmaceutical

Contract Manufacturing by Dosage Form - Injectables

(Injections, Vials & Intravenous Solutions), Solid Dosage

Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage

Forms (Syrups, Suspensions, Gels, Creams & Ointments)

Independently Analyzed with Annual Revenue Figures in US$

Thousand for the Years 2006 through 2012 (includes

corresponding Graph/Chart) III-35

Table 39: Rest of World 15-Year Perspective for

Pharmaceutical Contract Manufacturing by Dosage Form -

Percentage Breakdown of Annual Revenues for Injectables

(Injections, Vials & Intravenous Solutions), Solid Dosage

Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage

Forms (Syrups, Suspensions, Gels, Creams & Ointments) for

the Years 2006, 2014 and 2020 (includes corresponding

Graph/Chart) III-36

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 92

The United States (34)

Canada (3)

Japan (4)

Europe (33)

- France (3)

- Germany (8)

- The United Kingdom (9)

- Italy (3)

- Rest of Europe (10)

Asia-Pacific (Excluding Japan) (18)

To order this report: Global Pharmaceutical Contract Manufacturing Industry

http://www.reportlinker.com/p02284882/Global-Pharmaceutical-Contract-Manufacturing-Industry.html

Contact Clare: clare@reportlinker.com US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker
COPYRIGHT 2014 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:90ASI
Date:Aug 12, 2014
Words:3945
Previous Article:Metal Finishing Chemicals, Global Industry Analysts.
Next Article:Global Biopesticides Industry.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters